Small Cap Cancer Company Genenta Science 'Hijacks Tumors From Within,' Analyst HC Wainwright Says - Genenta Science (NASDAQ:GNTA)

HC Wainwright has initiated coverage on Genenta Science SpA GNTA with a Buy rating and a price target of $25.
"We like Genenta's approach as we believe it presents key advantages and differentiating elements when compared to other cellular therapies in the oncology space:
- It leverages a subpopulation of tumor-associated myeloid cells (TEMs), which promote angiogenesis, tumor growth and inhibit anti-tumor immune responses.
- It is built using an embedded regulatory mechanism to control transgene expression and avoid off-target and systemic toxicity.
- It has the potential for long-term durability.
- It is agnostic as it is not restricted to a preselected tumor antigen or a specific tumor type; therefore, it may find broad application for various malignancies.
In May, Genenta Science's ongoing trial of Temferon in glioblastoma multiforme patients with an unmethylated MGMT gene promoter has escalated to the next planned dose.
With no drug-limiting toxicities observed at lower doses, Genenta has now dosed the first patient in a new cohort (cohort 6) with 3.0 x 106 Temferon cells per kilogram, 50% higher than the highest prior level.
Genenta expects to complete enrollment and dosing in cohorts 6 and 7 by the end of the first half of 2023.
Price Action: GNTA shares are down 9.35% at $6.11 during the market session on the last check Monday.

This Small Cap Cancer Company 'Hijacks Tumors From Within," HC Wainwright Says